RxDoctor Payments Data

Sergio Abarca, MD

Family Medicine · Tooele, UTNPI 1245238617

Payments from drug & device makers

$6,874in general payments, 2019–2025

Across 423 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$916
  • Amgen$633
  • Lilly USA, LLC$574
  • Novo Nordisk$443
  • AstraZeneca$441
  • Medtronic$394
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$6,854100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,874 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$54,797
Medicare patients
139
Services billed
4,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide59$72,595
EliquisApixaban72$69,417
JardianceEmpagliflozin59$59,586
OzempicSemaglutide52$50,221
MounjaroTirzepatide27$35,048
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$25,948
KerendiaFinerenone18$19,804
FarxigaDapagliflozin Propanediol24$18,932
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$15,727
Xultophy 100-3.6Insulin Degludec/Liraglutide12$14,225
XareltoRivaroxaban15$12,589
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$9,219
Janumet XrSitagliptin Phos/Metformin Hcl24$9,190
LinzessLinaclotide16$8,684
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$7,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$574$107,64286 claims
PfizerEliquis$329$69,41772 claims
Novo NordiskOzempic, Xultophy 100-3.6$443$64,44664 claims
Boehringer IngelheimJardiance$289$59,58659 claims
GSKTrelegy Ellipta, Anoro Ellipta$131$28,56836 claims
BayerKerendia$324$19,80418 claims
AstraZenecaFarxiga$441$18,93224 claims
Johnson & JohnsonXarelto$142$12,58915 claims
MerckJanumet Xr$127$9,19024 claims
AbbVieLinzess$916$8,68416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.

Other family medicine in Tooele

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →